Switch theme
Sign up to access all valuation multiples
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
2009
583
LTM Revenue $126M
LTM EBITDA -$67.3M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascentage Pharma Group has a last 12-month revenue of $126M and a last 12-month EBITDA of -$67.3M.
In the most recent fiscal year, Ascentage Pharma Group achieved revenue of $28.5M and an EBITDA of -$95.6M.
Ascentage Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascentage Pharma Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $27.0M | $28.5M | XXX | XXX | XXX |
| Gross Profit | $3.2M | $24.1M | XXX | XXX | XXX |
| Gross Margin | 12% | 85% | XXX | XXX | XXX |
| EBITDA | -$99.2M | -$95.6M | XXX | XXX | XXX |
| EBITDA Margin | -368% | -335% | XXX | XXX | XXX |
| Net Profit | -$101M | -$114M | XXX | XXX | XXX |
| Net Margin | -373% | -398% | XXX | XXX | XXX |
| Net Debt | n/a | $38.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ascentage Pharma Group's stock price is HKD 38 (or $5).
Ascentage Pharma Group has current market cap of HKD 13.4B (or $1.7B), and EV of HKD 13.8B (or $1.8B).
See Ascentage Pharma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.7B | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ascentage Pharma Group has market cap of $1.7B and EV of $1.8B.
Ascentage Pharma Group's trades at 15.1x LTM EV/Revenue multiple, and -28.3x LTM EBITDA.
Analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ascentage Pharma Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 62.4x | XXX | XXX | XXX |
| EV/EBITDA | -18.6x | XXX | XXX | XXX |
| P/E | -14.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAscentage Pharma Group's NTM/LTM revenue growth is 25%
Ascentage Pharma Group's revenue per employee for the last fiscal year averaged $49K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Ascentage Pharma Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ascentage Pharma Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -335% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -310% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $49K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 88% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 82% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 318% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 479% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascentage Pharma Group acquired XXX companies to date.
Last acquisition by Ascentage Pharma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascentage Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ascentage Pharma Group founded? | Ascentage Pharma Group was founded in 2009. |
| Where is Ascentage Pharma Group headquartered? | Ascentage Pharma Group is headquartered in Hong Kong. |
| How many employees does Ascentage Pharma Group have? | As of today, Ascentage Pharma Group has 583 employees. |
| Who is the CEO of Ascentage Pharma Group? | Ascentage Pharma Group's CEO is Dr. Dajun Yang, M.D.,PhD. |
| Is Ascentage Pharma Group publicy listed? | Yes, Ascentage Pharma Group is a public company listed on HKG. |
| What is the stock symbol of Ascentage Pharma Group? | Ascentage Pharma Group trades under 06855 ticker. |
| When did Ascentage Pharma Group go public? | Ascentage Pharma Group went public in 2019. |
| Who are competitors of Ascentage Pharma Group? | Similar companies to Ascentage Pharma Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ascentage Pharma Group? | Ascentage Pharma Group's current market cap is $1.7B |
| What is the current revenue of Ascentage Pharma Group? | Ascentage Pharma Group's last 12-month revenue is $126M. |
| What is the current EBITDA of Ascentage Pharma Group? | Ascentage Pharma Group's last 12-month EBITDA is -$67.3M. |
| What is the current EV/Revenue multiple of Ascentage Pharma Group? | Current revenue multiple of Ascentage Pharma Group is 15.1x. |
| What is the current EV/EBITDA multiple of Ascentage Pharma Group? | Current EBITDA multiple of Ascentage Pharma Group is -28.3x. |
| What is the current revenue growth of Ascentage Pharma Group? | Ascentage Pharma Group revenue growth between 2023 and 2024 was 6%. |
| Is Ascentage Pharma Group profitable? | Yes, Ascentage Pharma Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
